Optimizing Efficacy to Safety Ratio of Glucocorticoids in Rheumatoid Arthritis Models by Leveraging Peroxisome Proliferator–Activated Nuclear Receptor‐α Agonism
Authors' conclusion
GW enhances the anti-inflammatory effects of glucocorticoids in L929sA cells and mitigates metabolic side effects of dexamethasone in vivo, without compromising efficacy. In human OA-FLS and RA-FLS, this combination cooperatively regulates metabolic gene expression. Moreover, PPARα agonism permits to broaden its anti-inflammatory profile to interferon-driven pathways.
Study context
- Population
- TNFα-stimulated L929sA fibroblasts, primary human fibroblast-like synoviocytes (FLS) from patients with osteoarthritis (OA) and rheumatoid arthritis (RA), and collagen-induced arthritis mice
- Comparison
- Dexamethasone plus PPARα agonist GW7647 vs dexamethasone alone
Methodological detailsfour model systems, in vitro and in vivo
- Four model systems
- In vitro and in vivo
Main finding
As reported in the abstract
- Dexamethasone reduced the inflammatory TNFα response in L929sA cells, further potentiated by GW7647
- In vivo, dexamethasone induced adiposity and hypertriglyceridemia, which GW7647 counteracted without affecting arthritis severity
- In OA-FLS and RA-FLS, dexamethasone and GW7647 cooperatively regulated metabolic gene expression
- In TNFα-stimulated human OA-FLS, combined dexamethasone and GW suppressed interferon-stimulated proteins (proteomics)
- Suppression of proinflammatory gene expression by the combination was more outspoken in L929sA co-stimulated with TNFα and interferon-β than with TNFα alone
Original publication
Optimizing Efficacy to Safety Ratio of Glucocorticoids in Rheumatoid Arthritis Models by Leveraging Peroxisome Proliferator–Activated Nuclear Receptor‐α Agonism. Arthritis Rheumatol. Published 7 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →